Allspring Global Investments Reduces Stake in Neurocrine Biosciences

Institutional investor trims position in biotech firm by over 11% in Q4 2025

Apr. 2, 2026 at 7:08am

Got story updates? Submit your updates here. ›

Allspring Global Investments Holdings LLC reduced its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 11.2% during the fourth quarter of 2025, according to a recent SEC filing. The firm now owns 339,432 shares of the biopharmaceutical company's stock, worth approximately $47.7 million.

Why it matters

Neurocrine Biosciences is a prominent biotech firm focused on developing treatments for neurological and psychiatric disorders. Changes in institutional ownership can signal shifts in investor sentiment and provide insights into the company's performance and outlook.

The details

Allspring Global Investments sold 43,009 shares of Neurocrine Biosciences during the quarter, reducing its total position to 339,432 shares. The firm now owns approximately 0.34% of the company's outstanding stock. Neurocrine Biosciences is a $13.3 billion company that markets the movement disorder drug Ingrezza and has a robust pipeline of neurological and endocrine product candidates.

  • Allspring Global Investments filed its 13F report for the fourth quarter of 2025 on April 2, 2026.

The players

Allspring Global Investments Holdings LLC

A global investment management firm that oversees over $600 billion in client assets.

Neurocrine Biosciences, Inc.

A biopharmaceutical company focused on developing treatments for neurological and psychiatric disorders.

Got photos? Submit your photos here. ›

What they’re saying

“Neurocrine Biosciences has a promising pipeline of neurological and endocrine product candidates, but the stock's valuation has been volatile in recent quarters.”

— Analyst

The takeaway

This filing highlights the shifting landscape of institutional ownership in the biotech sector, as investors carefully monitor the performance and prospects of companies like Neurocrine Biosciences.